A dietary supplement used to build muscle – or prevent muscle loss as a result of ageing or illness – is to be trialled as a potential treatment for chronic liver disease.

Major barriers in screening for fatty liver disease in patients with HIV included uncertainties about testing, diagnostic ...

Liver cancer is the sixth most common cancer in the world and the 16th most common in the UK - but it is often detected too ...

In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Data from 22 studies, encompassing 756,088 subjects, including 62,072 Hispanic adults, revealed striking findings. The pooled ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...

A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future risk of developing serious liver ...

Exposure to environmental chemicals during pregnancy may increase the risk for liver injury and steatosis in children and mothers, which could be mitigated by higher folic acid supplementation, ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...